Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans trimmed its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 16,312 shares of the medical equipment provider’s stock after selling 435 shares during the period. Thrivent Financial for Lutherans’ holdings in Lantheus were worth $1,790,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Farallon Capital Management LLC grew its stake in Lantheus by 53.7% during the second quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock worth $182,999,000 after buying an additional 796,000 shares during the period. Dimensional Fund Advisors LP boosted its position in Lantheus by 1.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider’s stock worth $99,525,000 after purchasing an additional 19,071 shares during the period. Swedbank AB boosted its position in Lantheus by 21.1% during the 3rd quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock worth $79,266,000 after purchasing an additional 125,843 shares during the period. Boston Partners increased its holdings in Lantheus by 21.2% in the 1st quarter. Boston Partners now owns 681,281 shares of the medical equipment provider’s stock valued at $42,696,000 after purchasing an additional 119,156 shares in the last quarter. Finally, LSV Asset Management raised its position in Lantheus by 27.9% in the second quarter. LSV Asset Management now owns 640,950 shares of the medical equipment provider’s stock valued at $51,462,000 after purchasing an additional 139,647 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on LNTH. Truist Financial reiterated a “buy” rating and set a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Redburn Atlantic started coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target on the stock. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, JMP Securities cut their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and an average price target of $122.50.

Lantheus Stock Down 1.1 %

Shares of LNTH opened at $89.27 on Friday. The firm has a market capitalization of $6.21 billion, a PE ratio of 15.02 and a beta of 0.51. The firm has a 50-day moving average price of $101.76 and a 200 day moving average price of $97.04. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.